Skip to main content
. Author manuscript; available in PMC: 2012 Sep 10.
Published in final edited form as: Mol Ther. 2008 Jul 29;16(10):1665–1673. doi: 10.1038/mt.2008.162

Figure 1. Suppression of all immune cell types was observed in animals receiving cyclophosphamide (CP).

Figure 1

An antitumor efficacy study was conducted in which parallel groups of immunocompetent and immunosuppressed hamsters were treated with intratumoral injections of VRX-007, wild-type adenovirus serotype 5 (Ad5), or vehicle. In this study, the first dose of CP was given on day −4 and was followed by twice weekly CP dosing throughout the study. Intratumoral oncolytic Ad (or vehicle) injections were administered on days 0, 1, 2, 4–6. The tumor suppression data are shown in Figure 2. Blood was collected and hematological analysis was performed on days −4, 8, 20, and 34 to monitor immunosuppression. The counts of total white blood cells (a), neutrophils (b), lymphocytes (c), and monocytes (d) are shown. No basophils were observed. The data are shown as the mean of each treatment group, ±SEM, n = 6/group. The legend for all panels is shown in a.